Chemical proteomic analysis reveals alternative modes of action for pyrido[2,3-d]pyrimidine kinase inhibitors

Molecular and Cellular Proteomics

Volumn 3, Issue 12, 2004, Pages 1181-1193

  Wissing, Josef ^a   Godl, Klaus ^a   Brehmer, Dirk ^a   Blencke, Stephanie ^a   Weber, Martina ^a   Habenberger, Peter ^a   Stein Gerlach, Matthias ^a   Missio, Andrea ^a   Cotten, Matt ^a   Müller, Stefan ^a   Daub, Henrik ^a  

^a Axxima Pharmaceuticals AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

6 (2,6 DICHLOROPHENYL) 2 (4 FLUORO 3 METHYLANILINO) 8 METHYL 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE P38; PD 166285; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN KINASE; PROTEIN SERINE THREONINE KINASE; PYRIDO[2,3 D]PYRIMIDINE DERIVATIVE; REGULATOR PROTEIN; THREONINE; UNCLASSIFIED DRUG;

AFFINITY CHROMATOGRAPHY; ANIMAL CELL; ARTICLE; CELL CULTURE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; GEL ELECTROPHORESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; MASS SPECTROMETRY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEOMICS; SIGNAL TRANSDUCTION;

ADENOSINE TRIPHOSPHATE; AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BINDING SITES; CELL LINE, TUMOR; CELLS, CULTURED; CHROMATOGRAPHY, LIQUID; COS CELLS; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME INHIBITORS; HELA CELLS; HUMANS; INFLAMMATION; INHIBITORY CONCENTRATION 50; LIGANDS; LIPOPOLYSACCHARIDES; MASS SPECTROMETRY; MODELS, CHEMICAL; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; PLASMIDS; POLYETHYLENE GLYCOLS; PROTEIN KINASE INHIBITORS; PROTEOMICS; PYRIDINES; PYRIMIDINES; SEQUENCE HOMOLOGY, AMINO ACID; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 19944433530     PISSN: 15359476     EISSN: None     Source Type: Journal    
DOI: 10.1074/mcp.M400124-MCP200     Document Type: Article

References (46)

1. Cohen, P. (2002) Protein kinases - the major drug targets of the twenty-first century? Nat. Rev. Drug Discov. 1, 309-315
2. Capdeville, R., Buchdunger, E., Zimmermann, J., and Matter, A. (2002) Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat. Rev. Drug Discov. 1, 493-502
3. Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., and Sawyers, C. L. (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293, 876-880
4. Shah, N. P., Nicoll, J. M., Nagar, B., Gorre, M. E., Pacquette, R. L., Kuriyan, J., and Sawyers, C. L. (2002) Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2, 117-125
5. von Bubnoff, N., Schneller, F., Peschel, C., and Duyster J. (2002) BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: A prospective study. Lancet 359, 487-491
6. Dorsey, J. F., Jove, R., Kraker, A. J., and Wu, J. (2000) The pyrido[2,3-d]-pyrimidine derivative PD180970 inhibits p210Bcr-Abl tyrosine kinase and induces apoptosis of K562 leukemic cells. Cancer Res. 60, 3127-3131
7. Panek, R. L., Lu, G. H., Klutschko, S. R., Batley, B. L., Dahring, T. K., Hamby, J. M., Hallak, H., Doherty, A. M., and Keiser, J. A. (1997) In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor. J. Pharmacol. Exp. Ther. 283, 1433-1444
8. Klutschko, S. R., Hamby, J. M., Boschelli, D. H., Wu, Z., Kraker, A. J., Amar, A. M., Hartl, B. G., Shen, C., Klohs, W. D., Steinkampf, R. W., Driscoll, D. L., Nelson, J. M., Elliott, W. L., Roberts, B. J., Stoner, C. L., Vincent, P. W., Dykes, D. J., Panek, R. L., Lu, G. H., Major, T. C., Dahring, T. K., Hallak, H., Bradford, L., Showalter, H. D. H., and Doherty, A. M. (1998) 2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. Structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity. J. Med. Chem. 41, 3276-3292
9. Wisniewski, D., Lambek, C. L., Liu, C., Strife, A., Veach, D., R., Nagar, B., Young, M. A., Schindler, T., Bornmann, W. G., Bertino, J. R., Kuriyan, J., and Clarkson, B. (2002) Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases. Cancer Res. 62, 4244-4255
10. La Rosée, P., Corbin, A. S., Stoffregen, E. P., Deininger, M. W., and Druker, B. J. (2002) Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571). Cancer Res. 62, 7149-7153
11. Branford, S., Rudzki, Z., Walsh, S., Grigg, A., Arthur, C., Taylor, K., Herrmann, R., Lynch, K. P., and Hughes, T. P. (2002) High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 99, 3472-3475
12. Hofmann, W.-K., Jones, L. C., Lemp, N. A., de Vos, S., Gschaidmeier, H., Hoelzer, D., Ottmann, O. G., and Koeffler, H. P. (2002) Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. Blood 99, 1860-1862
13. Dimitroff, C. J., Klohs, W., Sharma, A., Pera, P., Driscol, I D., Veith, J., Steinkampf, R., Schroeder, M., Klutchko, S., Sumlin, A., Henderson, B., Dougherty, T. J., and Bernacki, R. J. (1999) Anti-angiogenic activity of selected receptor tyrosine kinase inhibitors, PD166285 and PD173074: implications for combination treatment with photodynamic therapy. Invest. New Drugs 17, 121-135
14. Kraker, A. J., Roberts, B. J., Vincent, P. W., Patmore, S. J., and Elliott, W. (1999) In vivo antitumor activity of selective c-src tyrosine kinase (TK) inhibitors. Proc. Am. Assoc. Cancer Res. 40, 808
15. Davies, S. P., Reddy, H., Caivano, M., and Cohen, P. (2000) Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 351, 95-105
16. Bain, J., McLauchlan, H., Elliott, M., and Cohen, P. (2003) The specificities of protein kinase inhibitors: An update. Biochem. J. 371, 199-204
17. Manning, G., Whyte, D. B., Martinez, R., Hunter, T., and Sudarsanam, S. (2002) The protein kinase complement of the human genome. Science 298, 1912-1934
18. Knockaert, M., Gray, N., Damiens, E., Chang, Y.-T., Grellier, P., Grant, K., Fergusson, D., Mottram, J., Soete, M., Dubremetz, K.-F., Le Roch, K., Doerig, C., Schultz, P. G., and Meijer, L. (2000) Intracellular targets of cyclin-dependent kinase inhibitors: Identification by affinity chromatography using immobilised inhibitors. Chem. Biol. 7, 411-422
19. Knockaert, M., Wieking, K., Schmitt, S., Leost, M., Grant, K. M., Mottram, J. C., Kunick, C., and Meijer, L. (2002) Intracellular targets of paullones. Identification following affinity purification on immobilized inhibitor. J. Biol. Chem. 277, 25493-25501
20. Brown, D., and Superti-Furga, G. (2003) Rediscovering the sweet spot in drug discovery. Drug Discov. Today 8, 1067-1077
21. Wan, Y., Hur, W., Cho, C. Y., Liu, Y., Adrian, F. J., Lozach, O., Bach, S., Mayer, T., Fabbro, D., Meijer, L., and Gray, N. S. (2004) Synthesis and target identification of hymenialdisine analogs. Chem. Biol. 11, 247-259
22. Godl, K., Wissing, J., Kurtenbach, A., Habenberger, P., Blencke, S., Gutbrod, H., Salassidis, K., Stein-Gerlach, M., Missio, A., Cotten, M., and Daub, H. (2003) An efficient proteomics method to identify the cellular targets of protein kinase inhibitors. Proc. Natl. Acad. Sci. U. S. A. 100, 15434-15439
23. Brehmer, D., Godl, K., Zech, B., Wissing, J., and Daub, H. (2004) Proteome-wide identification of cellular targets affected by bisindolylmaleimide-type protein kinase C inhibitors. Mol. Cell. Proteomics 3, 490-500
24. Godl, K., and Daub, H. (2004) Proteomic analysis of kinase inhibitor selectivity and function. Cell Cycle 3, 393-395
25. Cotten, M., Stegmueller, K., Eickhoff, J., Herzberger, K., Herget, T., Choidas, A., Daub, H., and Godl, K. (2003) Exploiting features of adenovirus replication to support mammalian kinase production. Nucleic Acids Res. 31, e128
26. Blencke, S., Zech, B., Engkvist, O., Greff, Z., Orfi, L., Horvath, Z., Keri, G., Ullrich, A., and Daub, H. (2004) Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors. Chem. Biol. 11, 691-701
27. Daub, H., Blencke, S., Habenberger, P., Kurtenbach, A., Dennenmoser, J., Wissing, J., Ullrich, A., and Cotten, M. (2002) Identification of SRPK1 and SRPK2 as the major cellular protein kinases phosphorylating hepatitis B virus core protein. J. Virol. 76, 8124-8137
28. Beardsley, R. L., and Reilly, J. P. (2002) Optimization of guanidination procedures for MALDI mass mapping. Anal. Chem. 74, 1884-1890
29. Wang, Y., Li, R., Booher, R. N., Kraker, A., Lawrence, T., Leopold, W. R., and Sun, Y. (2001) Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator. Cancer Res. 61, 8211-8217
30. Nagar, B., Bornmann, W. G., Pellicena, P., Schindler, T., Veach, D. R., Miller, W. T., Clarkson, B., and Kuriyan, J. (2002) Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res. 62, 4236-4243
31. Wang, Q., Smith, J. B., Harrison, M. L., and Geahlen, R. L. (1991) Identification of tyrosine 67 in bovine brain myelin basic protein as a specific phosphorylation site for thymus p56lck. Biochem. Biophys. Res. Commun. 178, 1393-1399
32. Superti-Furga, G., Fumagalli, S., Kögl, M., Courtneidge, S. A., and Draetta, G. (1993) Csk inhibition of c-Src activity requires both the SH2 and SH3 domains of Src. EMBO J. 12, 2625-2634
33. Schmidt, F., Donahoe, S., Hagens, K., Mattow, J., Schaible, U. E., Kaufmann, S. H., Aebersold, R., and Jungblut, P. R. (2004) Complementary analysis of the Mycobacterium tuberculosis proteome by two-dimensional electrophoresis and isotope-coded affinity tag technology. Mol. Cell. Proteomics 3, 24-42
34. Wang, J., Xue, Y., Feng, X., Li, X., Wang, H., Li, W., Zhao, C., Cheng, X., Ma, Y., Zhou, P., Yin, J., Bhatnagar, A., Wang, R., and Liu, S. (2004) An analysis of the proteomic profile for Thermoanaerobacter tengcongensis under optimal culture conditions. Proteomics 4, 136-150
35. Lee, J. C., Laydon, J. T., McDonell, P. C., Gallagher, T. F., Kumar, S., Green, D., McNulty, D., Blumenthal, M. J., Heys, J. R., Landvatter, S. W., Strickler, J. E., McLaughlin, M. M., Siemens, I. R., Fisher, S. M., Livi, G. P., White, J. R., Adams, J. L., and Young, P. R. (1994) A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372, 739-746
36. Chin, A. I., Dempsey, P. W., Bruhn, K., Miller, J. F., and Cheng, G. (2002) Involvement of receptor-interacting protein 2 in innate and adaptive immune responses. Nature 416, 190-194
37. Kobayashi, K., Inohara, N., Hernandez, L. D., Galan, J. E., Nunez, G., Janeway, C. A., Medzhitov, R., and Flavell, R. A. (2002) RICK/Rip2/CARDIAK mediates signalling for receptors of the innate and adaptive immune systems. Nature 416, 194-199
38. Eyers, P. A., van den Ijssel, P., Quinlan, R. A., Goedert, M., and Cohen, P. (1999) Use of a drug-resistant mutant of stress-activated protein kinase 2a/p38 to validate the in vivo specificity of SB 203580. FEBS Lett. 451, 191-196
39. Rutault, K., Hazzalin, C. A., and Mahadevan, L. C. (2001) Combinations of ERK and p38 MAPK inhibitors ablate tumor necrosis factor-α (TNF-α) mRNA induction. Evidence for selective destabilization of TNF-α transcripts. J. Biol. Chem. 276, 6666-6674
40. Kotlyarov, A., Neininger, A., Schubert, C., Eckert, R., Birchmeier, C., Volk, H.-D., and Gaestel, M. (1999) MAPKAP kinase 2 is essential for LPS-induced TNF-α biosynthesis. Nat. Cell Biol. 1, 94-97
41. Akira, S. (2003) Mammalian Toll-like receptors. Curr. Opin. Immunol. 15, 5-11
42. Servant, M. J., Grandvaux, N., tenOever, B. R., Duguay, D., Lin, R., and Hiscott, J. (2003) Identification of the minimal phosphoacceptor site required for in vivo activation of interferon regulatory factor 3 in response to virus and double-stranded RNA. J. Biol. Chem. 278, 9441-9447
43. Dancey, J., and Sausville, E.A. (2003) Issues and progress with protein kinase inhibitors for cancer treatment. Nat. Rev. Drug Discov. 2, 296-313
44. Fischer, O. M., Streit, S., Hart, S., and Ullrich, A. (2003) Beyond Herceptin and Gleevec. Curr. Opin. Chem. Biol. 7, 490-495
45. Hamby, J. M., Connolly, C. J., Schroeder, M. C., Winters, R. T., Showalter, H. D., Panek, R. L., Major, T. C., Olsewski, B., Ryan, M. J., Dahring, T., Lu, G. H., Keiser, J., Amar, A., Shen, C., Kraker, A. J., Slintak, V., Nelson, J. M., Fry, D. W., Bradford, L., Hallak, H., and Doherty, A. M. (1997) Structure-activity relationships for a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors. J. Med. Chem. 40, 2296-2303
46. Mohammadi, M., Froum, S., Hamby, J. M., Schroeder, M. C., Panek, R. L., Lu, G. H., Eliseenkova, A. V., Green, D., Schlessinger, J., and Hubbard, S. R. (1998) Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain. EMBO J. 17, 5896-5904